DaVita Receives a Hold from Merrill Lynch

By Austin Angelo

Merrill Lynch analyst Kevin Fischbeck reiterated a Hold rating on DaVita (NYSE: DVA) today and set a price target of $68. The company’s shares opened today at $61.42.

According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of 9.0% and a 66.7% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Health Insurance Innovations, WellCare Health Plans, and Surgery Partners Inc.

DaVita has an analyst consensus of Moderate Buy, with a price target consensus of $65.75.

DaVita’s market cap is currently $12.35B and has a P/E ratio of 17.78. The company has a book value ratio of 2.5148.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2016, Kent Thiry, the Chairman & CEO of DVA sold 32,880 shares for a total of $2,531,431.

DaVita, Inc. engages in the provision of medical care services. It operates through the Kidney Care and HealthCare Partners divisions. The Kidney Care division manages outpatient dialysis centers and offers laboratory and administrative services. The HealthCare Partners division caters to patients covered with health plans. The company was founded in 1994 and is headquartered in Denver, CO.